Understanding the mechanism of the broadspectrum antiviral activity of favipiravir (T-705): Key role of the F1 motif of the viral polymerase

Journal of Virology

Volumn 91, Issue 12, 2017, Pages

  Abdelnabi, Rana ^a   de Morais, Ana Theresa Silveira ^b   Leyssen, Pieter ^a   Imbert, Isabelle ^b   Beaucourt, Stéphanie ^c   Blanc, Hervé ^c   Froeyen, Mathy ^a   Vignuzzi, Marco ^c   Canard, Bruno ^b   Neyts, Johan ^a   Delang, Leen ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b AIX MARSEILLE UNIVERSITY   (France)

^c CNRS   (France)

Author keywords

CVB3; Favipiravir; Fidelity; Mutagenesis; RdRp

Indexed keywords

FAVIPIRAVIR; RNA DIRECTED RNA POLYMERASE; AMIDE; ANTIVIRUS AGENT; LYSINE; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CHIKUNGUNYA; CHIKUNGUNYA VIRUS; CONTROLLED STUDY; COXSACKIE VIRUS INFECTION; COXSACKIEVIRUS B3; DRUG EFFICACY; DRUG RECEPTOR BINDING; EC50; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; ANIMAL; ANTIVIRAL RESISTANCE; CHEMISTRY; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; ENTEROVIRUS B; ENZYMOLOGY; GENETICS; JAPAN; METABOLISM; MICROBIAL VIABILITY; MUTATION; PROTEIN MOTIF; VERO CELL LINE;

AMIDES; AMINO ACID MOTIFS; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CHIKUNGUNYA VIRUS; DRUG RESISTANCE, VIRAL; ENTEROVIRUS B, HUMAN; JAPAN; LYSINE; MICE; MICROBIAL VIABILITY; MUTAGENESIS; MUTATION; PYRAZINES; RNA REPLICASE; VERO CELLS; VIRUS REPLICATION;

EID: 85019750229     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00487-17     Document Type: Article

References (29)

1. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. 2013. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100:446-454. https://doi.org/10.1016/j.antiviral.2013.09.015
2. Rocha-Pereira J, Jochmans D, Dallmeier K, Leyssen P, Nascimento MSJ, Neyts J. 2012. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun 424:777-780. https://doi.org/10.1016/j.bbrc.2012.07.034
3. Zmurko J, Marques RE, Schols D, Verbeken E, Kaptein SJF, Neyts J. 2016. The viral polymerase inhibitor 7-deaza-2=-C-methyladenosine is a potent inhibitor of in vitro zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl Trop Dis 10:e0004695. https://doi.org/10.1371/journal.pntd.0004695
4. Safronetz D, Falzarano D, Scott DP, Furuta Y, Feldmann H, Gowen BB. 2013. Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrob Agents Chemother 57:4673-4680. https://doi.org/10.1128/AAC.00886-13
5. Mentré F, Taburet A-M, Guedj J, Anglaret X, Keïta S, de Lamballerie X, Malvy D. 2015. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis 15:150-151. https://doi.org/10.1016/S1473-3099(14)71047-3
6. Sangawa H, Komeno T, Nishikawa H, Yoshida A, Takahashi K, Nomura N, Furuta Y. 2013. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 57:5202-5208. https://doi.org/10.1128/AAC.00649-13
7. Arias A, Thorne L, Goodfellow I. 2014. Favipiravir elicits antiviral mutagenesis during virus replication in vivo. eLife 3:e03679. https://doi.org/10.7554/eLife.03679
8. Baranovich T, Wong S-S, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA. 2013. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 87:3741-3751. https://doi.org/10.1128/JVI.02346-12
9. Delang L, Segura Guerrero N, Tas A, Quérat G, Pastorino B, Froeyen M, Dallmeier K, Jochmans D, Herdewijn P, Bello F, Snijder EJ, de Lamballerie X, Martina B, Neyts J, van Hemert MJ, Leyssen P. 2014. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 69: 2770-2784. https://doi.org/10.1093/jac/dku209
10. Ferrer-Orta C, Agudo R, Domingo E, Verdaguer N. 2009. Structural insights into replication initiation and elongation processes by the FMDV RNA-dependent RNA polymerase. Curr Opin Struct Biol 19: 752-758. https://doi.org/10.1016/j.sbi.2009.10.016
11. Iglesias NG, Filomatori CV, Gamarnik AV. 2011. The F1 motif of dengue virus polymerase NS5 is involved in promoter-dependent RNA synthesis. J Virol 85:5745-5756. https://doi.org/10.1128/JVI.02343-10
12. Surana P, Satchidanandam V, Nair DT. 2014. RNA-dependent RNA polymerase of Japanese encephalitis virus binds the initiator nucleotide GTP to form a mechanistically important pre-initiation state. Nucleic Acids Res 42:2758-2773. https://doi.org/10.1093/nar/gkt1106
13. Gnädig NF, Beaucourt S, Campagnola G, Borderia A, Sanz-Ramos VM, Gong P, Blanc H, Peersen OB, Vignuzzi M. 2012. Coxsackievirus B3 mutator strains are attenuated in vivo. Proc Natl Acad Sci U S A 109: E2294-E2303. https://doi.org/10.1073/pnas.1204022109
14. Levi LI, Gnädig NF, Beaucourt S, McPherson MJ, Baron B, Arnold JJ, Vignuzzi M. 2010. Fidelity variants of RNA dependent RNA polymerases uncover an indirect, mutagenic activity of amiloride compounds. PLoS Pathog 6:e1001163. https://doi.org/10.1371/journal.ppat.1001163
15. Paeshuyse J, Dallmeier K, Neyts J. 2011. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr Opin Virol 1:590-598. https://doi.org/10.1016/j.coviro.2011.10.030
16. Vanderlinden E, Vrancken B, Van Houdt J, Rajwanshi VK, Gillemot SAG, Lemey P, Naesens L. 2016. Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis. Antimicrob Agents Chemother 60:6679-6691. https://doi.org/10.1128/AAC.01156-16
17. de ávila AI, Gallego I, Soria ME, Gregori J, Quer J, Esteban JI, Rice CM, Domingo E, Perales C. 2016. Lethal mutagenesis of hepatitis C virus induced by favipiravir. PLoS One 11:e0164691. https://doi.org/10.1371/journal.pone.0164691
18. Peersen OB. 2 February 2017. Picornaviral polymerase structure, function, and fidelity modulation. Virus Res https://doi.org/10.1016/j.virusres.2017.01.026
19. Arnold JJ, Vignuzzi M, Stone JK, Andino R, Cameron CE. 2005. Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J Biol Chem 280:25706-25716. https://doi.org/10.1074/jbc. M503444200
20. Thompson AA, Peersen OB. 2004. Structural basis for proteolysisdependent activation of the poliovirus RNA-dependent RNA polymerase. EMBO J 23:3462-3471. https://doi.org/10.1038/sj.emboj.7600357
21. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. 2005. Mechanism of action of T-705 against influenza virus mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49:981-986. https://doi.org/10.1128/AAC.49.3.981-986.2005
22. Naesens L, Guddat LW, Keough DT, van Kuilenburg ABP, Meijer J, Vande Voorde J, Balzarini J. 2013. Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol Pharmacol 84:615-629. https://doi.org/10.1124/mol.113.087247
23. Jin Z, Tucker K, Lin X, Kao CC, Shaw K, Tan H, Symons J, Behera I, Rajwanshi VK, Dyatkina N, Wang G, Beigelman L, Deval J. 2015. Biochemical evaluation of the inhibition properties of favipiravir (T-705) and 2=-C-methyl-cytidine triphosphates against human and mouse norovirus RNA polymerases. Antimicrob Agents Chemother 59:7504-7516. https://doi.org/10.1128/AAC.01391-15
24. Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. 2013. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5=-triphosphate towards influenza A virus polymerase. PLoS One 8:e68347. https://doi.org/10.1371/journal.pone.0068347
25. De Palma AM, Thibaut HJ, Van Der Linden L, Lanke K, Heggermont W, Ireland S, Andrews R, Arimilli M, Al-Tel TH, De Clercq E, Van Kuppeveld F, Neyts J. 2009. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother 53:1850-1857. https://doi.org/10.1128/AAC.00934-08
26. JabafiI, Selisko B, Coutard B, De Palma AM, Neyts J, EgloffMP, Grisel S, Dalle K, Campanacci V, Spinelli S, Cambillau C, Canard B, Gruez A. 2007. Improved crystallization of the coxsackievirus B3 RNA-dependent RNA polymerase. Acta Crystallogr Sect F Struct Biol Cryst Commun 63: 495-498. https://doi.org/10.1107/S1744309107020416
27. Arnold JJ, Cameron CE. 2000. Poliovirus RNA-dependent RNA polymerase (3Dpol). Assembly of stable, elongation-competent complexes by using a symmetrical primer-template substrate (sym/sub). J Biol Chem 275:5329-5336
28. Gong P, Campagnola G, Peersen OB. 2009. A quantitative stopped-flow fluorescence assay for measuring polymerase elongation rates. Anal Biochem 391:45-55. https://doi.org/10.1016/j.ab.2009.04.035
29. Isakov O, Bordería AV, Golan D, Hamenahem A, Celniker G, Yoffe L, Blanc H, Vignuzzi M, Shomron N. 2015. Deep sequencing analysis of viral infection and evolution allows rapid and detailed characterization of viral mutant spectrum. Bioinformatics 31:2141-2150. https://doi.org/10.1093/bioinformatics/btv101